[ad_1]
—— Demonstrated for the first time the long-term safety and disease control data of the Phase 3 TruE-AD study of Ruxotinib cream in the treatment of atopic dermatitis
Inset (Nasdaq stock code:INCY) Announced today that it will present multiple abstracts at the 2021 Revolutionary Atopic Dermatitis (RAD) Virtual Conference to be held on June 13th, highlighting Ruxotinib Cream (a research topical JAK1/ JAK2 inhibitor) updated data in patients with atopic dermatitis (AD), 2021.
“Atopic dermatitis is the most common type of eczema, which can be difficult to control and can have a significant impact on patients’ lives,” said Jim Lee, MD, vice president of Incyte’s Inflammation and Autoimmune Group. “We are excited to share new data from our Phase 3 TruE-AD program at the RAD virtual meeting. These data provide more insights into the potential role of ruxolitinib cream as a treatment option for patients with atopic dermatitis.”
The main summary includes:
The latest oral and poster presentations
Long-term safety and disease control of Ruxolitinib cream in the treatment of atopic dermatitis: results of two phase 3 studies
Poster display
Long-term safety and disease control of ruxotinib cream in patients with more severe atopic dermatitis: pooled results from two phase 3 studies
Long-term safety and disease control of ruxotinib cream in patients with atopic dermatitis based on previous medication history: pooled results of two phase 3 studies
Predict productivity loss and indirect cost reduction in patients with atopic dermatitis treated with Ruxotinib cream
Inadequate disease control, unsatisfactory treatment, and impaired quality of life in American patients receiving topical treatment for atopic dermatitis
For more information about virtual meetings, please visit the RAD website: https://revolutionizingad.com/In addition, the conference summary will be published in British Journal of Dermatology.
About Ruxortinib Cream
Ruxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, designed for topical application. Ruxolitinib cream is currently in the third phase of development for the treatment of adolescents and adults with atopic dermatitis (TRuE-AD) and vitiligo (TRuE-V). Incyte has global rights to the development and commercialization of ruxolitinib cream.
About Inset Dermatology
Incyte’s science-first methods and immunology expertise form the company’s foundation. In dermatology, the company’s research and development efforts are focused on using our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies that have the potential to modulate immune pathways, leading to uncontrolled inflammation and helping to restore normal immunity Features.
Currently, Incyte is exploring the potential of JAK to inhibit many immune-mediated skin diseases with high unmet medical needs, including atopic dermatitis, leukoplakia, and hidradenitis suppurativa.To learn more, please visit Dermatology at Incyte.com.
About Inset
Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware, focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapies.For more information about Incyte, please visit Inset And follow @Incyte.
Forward-looking statements
In addition to the historical information described in this article, the matters described in this press release include data on the company’s ongoing clinical development of Ruxotinib cream, TRuE-AD and TruE-V projects and their atopic dermatitis Presented statement, vitiligo and other dermatological items, and whether or when Ruxotinib cream will be approved or marketed in the United States or elsewhere for the treatment of atopic dermatitis, vitiligo or any other indication, including predictions , Estimates and other forward-looking statements.
These forward-looking statements are based on the company’s current expectations and are subject to risks and uncertainties that may cause significant differences in actual results, including unexpected developments and related risks in the following areas: unexpected delays; further research and development and clinical trials The results may be unsuccessful or insufficient to meet applicable regulatory standards or need to continue to develop; the ability to recruit a sufficient number of subjects in clinical trials; the impact of the COVID-19 pandemic and the measures to respond to the pandemic on the company’s clinical trials and supply The impact of the chain, other third-party suppliers, and development and discovery business; decisions made by the US FDA and other regulatory agencies outside the US; the efficacy or safety of the company’s products; the acceptance of the company’s products in the market; market competition; sales , Marketing, manufacturing and distribution requirements; and other risks detailed in the company’s reports to the US Securities and Exchange Commission from time to time, including its annual report and its quarterly report on Form 10-Q for the quarter ended March 31, 2021. The company does not undertake any intent or obligation to update these forward-looking statements.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20210612005013/en/
[ad_2]
Source link
